Asset Details
Do you wish to reserve the book?
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Do you wish to request the book?
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
2013
Overview
Background. Adenovirus serotype 26 (Ad26) has been developed as a novel candidate vaccine vector for human immunodeficiency virus type 1 (HIV-1) and other pathogens. The primary safety and immunogenicity data from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the firstin-human evaluation of a prototype Ad26 vector-based vaccine expressing clade A HIV-1 Env (Ad26. ENVA. 01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26. ENVA. 01 in humans. Methods. Samples from the IPCAVD 001 trial were used for humoral and cellular immunogenicity assays. Results. We observed a dose-dependent expansion of the magnitude, breadth, and epitopic diversity of Envspecific binding antibody responses elicited by this vaccine. Antibody-dependent cell-mediated phagocytosis, virus inhibition, and degranulation functional activity were also observed. Env-specific cellular immune responses induced by the vaccine included multiple CD8⁺ and CD4⁺ T-lymphocyte memory subpopulations and cytokine secretion phenotypes, although cellular immune breadth was limited. Baseline vector-specific T-lymphocyte responses were common but did not impair Env-specific immune responses in this study. Conclusion. Ad26. ENVA. 01 elicited a broad diversity of humoral and cellular immune responses in humans. These data support the further clinical development of Ad26 as a candidate vaccine vector.
Publisher
Oxford University Press
Subject
/ Adenoviruses, Human - classification
/ Adenoviruses, Human - genetics
/ AIDS Vaccines - administration & dosage
/ AIDS Vaccines - adverse effects
/ Biological and medical sciences
/ Fundamental and applied biological sciences. Psychology
/ Gene Products, env - genetics
/ Gene Products, env - immunology
/ HIV Infections - prevention & control
/ HIV/AIDS
/ Human immunodeficiency virus 1
/ Humans
/ Immunity, Cellular - immunology
/ Leukocytes, Mononuclear - immunology
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, Synthetic - administration & dosage
/ Vaccines, Synthetic - adverse effects
/ Vaccines, Synthetic - immunology
/ Virology
